ARTICLE | Company News
Gruenenthal, Forest Laboratories deal
December 15, 2014 8:00 AM UTC
Gruenenthal and Actavis plc (NYSE:ACT, Dublin, Ireland) terminated a 2010 deal granting Actavis’ subsidiary, Forest Laboratories, exclusive rights to co-develop and commercialize cebranopadol ( GRT60...